Nuformix PLC (LSE:NFX) said it appointed its co-founder and former chief executive officer Dr Daniel Gooding as an executive director with effect from 1 August this year.
The pharmaceutical development company also named Dr Julian Gilbert, currently a non-executive director, as non-executive chairman.
Gooding was Nuformix's CEO until June 2020 and has been acting as a consultant to the company since March 2022.
He instigated the company’s NXP002 programme as an inhaled therapy for the treatment of Idiopathic Pulmonary Fibrosis (IPF) and has over 22 years' experience in commercialisation and business development within the pharmaceutical industry.
He received his PhD in chemistry from Leeds University.
Since June 2020, Gooding has remained close to the fields of fibrosis, oncology and drug repurposing, Nuformix said.
Following the appointments, the Nuformix board will comprise non-executive chairman Gilbert, executive director Gooding and non-executive director Maddy Kennedy.
READ: Nuformix gets two presentations approved for leading international respiratory congress
“I am pleased that Dan has agreed to join the board as an executive director. He brings significant history with Nuformix and experience to the table which will help facilitate the progression of our assets, and in particular our NXP002 programme,” said chairman Gilbert.
“I believe that we now have a board and management structure appropriate for the company's needs in order to optimise value from its assets while maintaining tight control of costs.”